Precision Medicine Market to Witness Robust Expansion by 2026

Pharmaceutical
excipients are critical components of a pharmaceutical dosage form,
ensuring drug safety and efficacy. Therefore, compatibility with API,
adjacent excipients and dosage form are essential factors that need
to be considered while selecting an excipient. Various types of
excipients are used in a pharmaceutical formulations. This includes
binders, diluents, glidents, disintegrants, emulsifiers, compressing
agents, taste masking agents, lubricants, coating agents, sweeteners,
and vehicles (base). Use of excipients is high in oral and topical
dosage forms compared to parenteral. These excipients are extracted
from different sources such as plant, animals, and minerals or are
synthetically developed. The International Pharmaceutical Excipients
Council (IPEC), formed in 1991, focuses on harmonizing manufacturing
standards for pharmaceutical excipients globally.
Get Exclusive
Sample Report at: http://bit.ly/2Xmlgqf
Market Dynamics
Demand for
high-quality excipients is more in developed economies, while
affordability is the key criteria considered for price sensitive
emerging economies. China has emerged as the largest supplier of
low-cost pharmaceutical API and excipients. India is the other fast
emerging market to which production of excipients is outsourced owing
to lower labor and production costs. North America and Europe lead
the market for excipients as the number of excipient manufacturers
are high in these regions. Moreover, high cost of manufactured
excipients generates higher revenue for these regions compared to
cost of material produced by manufacturers in Asia Pacific. However,
growing pharmaceutical drug price pressure across the globe is
expected to drive growth of the markets in China and India
characterized by high supply of low cost excipients.
Oral And Topical
Segment Is Driving The Pharmaceutical Excipients Market Growth
Excipients are
largely used in the production of oral dosage forms such as tablets,
capsules, and liquids when compared to parenteral dosage forms. The
growth of excipients usage in oral dosage forms is expected to be
7.2% over the forecast period. Local players entering the
pharmaceutical industry mark their entry with oral dosage forms, as
manufacturing of these are easier when compared to other dosage
forms. Economies such as India, Brazil, China, and U.S. are few major
pharmaceutical excipients markets, as they have large presence of
regional pharmaceutical players. Therefore, demand for excipients is
expected to be high in such economies. Moreover, growing topical
solutions (cream, gel, eye drops, skin patch) in dermatology and pain
management categories is also expected to increase the demand for
excipients, thereby driving growth of the market.
Patent Expiries
To Provide Opportunities For Pharmaceutical Excipient Manufacturers
Symbicort
(Budesonide/Formoterol Fumarate Dihydrate), Cialis (Tadalafi),
Velcade (Bortezomib), Alimta (Pemetrexed), Vytorin (Ezetimibe and
Simvastatin), Cubicin (Daptomycin), Reyataz (Atazanavir) and
Sandostatin LAR (Octreotide Acetate) are some of the major
blockbuster brands going off-patent in 2017. This will pave way for
generic brands boosting the demand for respective pharmaceutical
excipients. According to the McKinsey’s Global Generics report,
nearly US$ 97 billion of drugs will go off-patent during 2017 –
2019.
In addition, advent
of biosimilars would further propel growth of the pharmaceutical
excipients market. Companies are investing in development of
biosimilars to capitalize on this billion dollar market opportunity.
However, strict regulatory hold over approval of biosimilars is
slowing the approval of biosimilars being developed, in turn
hampering growth of the pharmaceutical excipients market.
Inquire Here
Before Purchase of Research Report @ http://bit.ly/2YsT15A
Growing demand
for low cost medicines
Affordable
healthcare is the primary objective of health regulators globally,
something that is propagated by various such initiatives in place
such as Obama Care Act and the actions of Drug Price Control Order
(DPCO) in India. The DPCO has capped the prices of over 467 drugs to
cater to unmet need of population with low income levels. According
to the IMS Health 2015 data, average price of branded products has
increased from US$ 71.91 in 2010 to US$ 91.92 in 2015. On the other
hand, average price of generic products has declined from US$ 26.23
in 2010 to US$ 20.92 in 2015. Pricing pressure and high competition
are major attributable factors to this decline. This has further
contributed to wards the growth of pharmaceutical excipients market.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
It is a very informative and useful post thanks it is good material to read this post increases my knowledge. Mobile Laboratory Phlebotomy Software
ReplyDelete